Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases

Nature Reviews Drug Discovery

Volumn 6, Issue 6, 2007, Pages 464-479

  Mazanetz, Michael P ^a   Fischer, Peter M ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 AZA 9 OXAFLUORENE; 5 (2 AMINO 4 PYRIMIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; 6 N (3,3 DIMETHYLALLYL)ADENINE; ALOISINE A; ALOISINE DERIVATIVE; ALSTERPAULLONE; AMYLOID PRECURSOR PROTEIN; BISARYLMALEIMIDE; CALPASTATIN; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; IMATINIB; INDIRUBIN 3' OXIME; INDIRUBIN DERIVATIVE; INDOLINONE DERIVATIVE; INDOLOCARBAZOLE DERIVATIVE; LITHIUM ION; MITOGEN ACTIVATED PROTEIN KINASE 1; OLOMOUCINE; PROTEIN P25; PURVALANOL A; PURVALANOL B; PYRAZOLO(1,5 A)PYRIDINE; PYRAZOLO(3,4 C)PYRIDINE; PYRROLO(2,3 B)PYRAZINE DERIVATIVE; ROSCOVITINE; SRN 003556; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BINDING AFFINITY; BIPOLAR DISORDER; BLOOD BRAIN BARRIER; CRYSTAL STRUCTURE; DEGENERATIVE DISEASE; DRUG BINDING; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GENE OVEREXPRESSION; HYDROGEN BOND; IC 50; MAXIMUM PLASMA CONCENTRATION; MICROTUBULE; NERVE CELL NECROSIS; NEUROPATHOLOGY; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SPINAL CORD INJURY; STRUCTURE ACTIVITY RELATION; TAUOPATHY;

ANIMALS; BIOLOGICAL AVAILABILITY; BRAIN; CYCLIN-DEPENDENT KINASE 5; DRUG DESIGN; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; NEURODEGENERATIVE DISEASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; TAU PROTEINS;

EID: 34447503455     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2111     Document Type: Review

References (164)

1. Drechsel, D. N., Hyman, A. A., Cobb, M. H. & Kirschner, M. W. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 3, 1141-1154 (1992).
2. Buee, L., Bussiere, T., Buee-Scherrer, V., Delacourte, A. & Hof, P. R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Rev. 33, 95-130 (2000).
3. Anderton, B. H. et al. Sites of phosphorylation in tau and factors affecting their regulation. Biochem. Soc. Symp. 67, 73-80 (2001).
4. Hardy, J. The relationship between amyloid and tau. J. Mol. Neurosci. 20, 203-206 (2003).
5. SantaCruz, K. et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481 (2005).
6. Trojanowski, J. Q. & Lee, V. M. Pathological tau: A loss of normal function or a gain in toxicity? Nature Neurosci. 8, 1136-1137 (2005).
7. Le Corre, S. et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc. Natl Acad. Sci. USA 103, 9673-9678 (2006).
8. Lee, V. M., Goedert, M. & Trojanowski, J. Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159 (2001).
9. Julien, J. P. Amyotrophic lateral sclerosis: Unfolding the toxicity of the misfolded. Cell 104, 581-591 (2001).
10. Kuljis, R. O. Alzheimers Disease. emedicine (2005).
11. Semple, D., Smyth, R., Burns, J., Darjee, R. & McIntosh, A. Oxford Handbook of Psychiatry (Oxford Univ. Press, 2005).
12. Alzheimer, A., Stelzmann, R. A., Schnitzlein, H. N. & Murtagh, F. R. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin. Anat. 8, 429-431 (1995).
13. Grimes, C. A. & Jope, R. S. The multifaceted roles of glycogen synthase kinase 3 in cellular signaling. Progr. Neurobiol. 65, 391-426 (2001).
14. Takashima, A. et al. Presenilin 1 associates with glycogen synthase kinase-3 and its substrate tau. Proc. Natl Acad. Sci. USA 95, 9637-9641 (1998).
15. Mandelkow, E. M. et al. Tau domains, phosphorylation, and interactions with microtubules. Neurobiol. Aging 16, 355-362 (1995).
16. Johnson, G. V. & Stoothoff, W. H. Tau phosphorylation in neuronal cell function and dysfunction. J. Cell Sci. 117, 5721-5729 (2004).
17. Churcher, I. Tau therapeutic strategies for the treatment of Alzheimer's disease. Curr. Top. Med. Chem. 6, 579-595 (2006).
18. Lau, L. F., Schachter, J. B., Seymour, P. A. & Sanner, M. A. Tau protein phosphorylation as a therapeutic target in Alzheimer's disease. Curr. Top. Med. Chem. 2, 395-415 (2002).
19. Lee, G. et al. Phosphorylation of tau by fyn: Implications for Alzheimer's disease. J. Neurosci. 24, 2304-2312 (2004).
20. Chin, J. et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 25, 9694-9703 (2005).
21. Spittaels, K. et al. Glycogen synthase kinase-3 phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J. Biol. Chem. 275, 41340-41349 (2000).
22. Shelton, S. B. & Johnson, G. V. Cyclin-dependent kinase-5 in neurodegeneration. J. Neurochem. 88, 1313-1326 (2004).
23. Perry, G. et al. Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport 10, 2411-2415 (1999).
24. Dhavan, R. & Tsai, L. H. A decade of CDK5. Nature Rev. Mol. Cell. Biol. 2, 749-759 (2001).
25. Tsai, L. H., Delalle, I., Caviness, V. S. Jr, Chae, T. & Harlow, E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371, 419-423 (1994).
26. Grant, P., Sharma, P. & Pant, H. C. Cyclin-dependent protein kinase 5 (Cdk5) and the regulation of neurofilament metabolism. Eur. J. Biochem. 268, 1534-1546 (2001).
27. Gilmore, E. C., Ohshima, T., Goffinet, A. M., Kulkarni, A. B. & Herrup, K. Cyclin-dependent kinase 5-deficient mice demonstrate novel developmental arrest in cerebral cortex. J. Neurosci. 18, 6370-6377 (1998).
28. Patzke, H. & Tsai, L.-H. Calpain-mediated cleavage of the cyclin-dependent kinase-5 activator p39 to p29. J. Biol. Chem. 277, 8054-8060 (2002).
29. Hashiguchi, M., Saito, T., Hisanaga, S. & Hashiguchi, T. Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J. Biol. Chem. 277, 44525-44530 (2002).
30. Ishiguro, K. et al. Identification of the 23 kDa subunit of tau protein kinase II as a putative activator of cdk5 in bovine brain. FEBS Lett. 342, 203-208 (1994).
31. Lee, M. S. et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405, 360-364 (2000).
32. Lew, J. et al. A brain-specific activator of cyclindependent kinase 5. Nature 371, 423-426 (1994).
33. Cruz, J. C., Tseng, H. C., Goldman, J. A., Shih, H. & Tsai, L. H. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40, 471-483 (2003).
34. Patrick, G. N. et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402, 615-622 (1999).
35. Pei, J. J. et al. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res. 797, 267-277 (1998).
36. Lee, K. Y. et al. Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci. Res. 34, 21-29 (1999).
37. Yamaguchi, H. et al. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/ glycogen synthase kinase-3 β and cyclindependent kinase 5, a component of TPK II. Acta Neuropathol. 92, 232-241 (1996).
38. Grynspan, F., Griffin, W. R., Cataldo, A., Katayama, S. & Nixon, R. A. Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease. Brain Res. 763, 145-158 (1997).
39. Tseng, H. C., Zhou, Y., Shen, Y. & Tsai, L. H. A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett. 523, 58-62 (2002).
40. Augustinack, J. C., Sanders, J. L., Tsai, L. H. & Hyman, B. T. Colocalization and fluorescence resonance energy transfer between cdk5 and AT8 suggests a close association in pre-neurofibrillary tangles and neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 61, 557-564 (2002).
41. Cruz, J. C. & Tsai, L. H. Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends. Mol. Med. 10, 452-458 (2004).
42. Takashima, A. et al. Involvement of cyclin dependent kinase 5 activator p25 on tau phosphorylation in mouse brain. Neurosci. Lett. 306, 37-40 (2001).
43. Ahlijanian, M. K. et al. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc. Natl Acad. Sci. USA 97, 2910-2915 (2000).
44. Noble, W. et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555-565 (2003).
45. Van den Haute, C. et al. Coexpression of human cdk5 and its activator p35 with human protein tau in neurons in brain of triple transgenic mice. Neurobiol. Dis. 8, 32-44 (2001).
46. Davis, P. K. & Johnson, G. V. Energy metabolism and protein phosphorylation during apoptosis: A phosphorylation study of tau and high-molecularweight tau in differentiated PC12 cells. Biochem. J. 340 51-58 (1999).
47. Davis, P. K. & Johnson, G. V. The microtubule binding of Tau and high molecular weight Tau in apoptotic PC12 cells is impaired because of altered phosphorylation. J. Biol. Chem. 274, 35686-35692 (1999).
48. Zhang, J. & Johnson, G. V. Tau protein is hyperphosphorylated in a site-specific manner in apoptotic neuronal PC12 cells. J. Neurochem. 75, 2346-2357 (2000).
49. Doble, B. W. & Woodgett, J. R. GSK-3: Tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116, 1175-1186 (2003).
50. Hardt, S. E. & Sadoshima, J. Glycogen synthase kinase-3β: A novel regulator of cardiac hypertrophy and development. Circ. Res. 90 1055-1063 (2002).
51. Nikoulina, S. E. et al. Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes 51, 2190-2198 (2002).
52. Bhat, R. V., Budd Haeberlein, S. L. & Avila, J. Glycogen synthase kinase 3: A drug target for CNS therapies. J. Neurochem. 89, 1313-1317 (2004).
53. Cohen, P. & Goedert, M. GSK3 inhibitors: Development and therapeutic potential. Nature Rev. Drug. Discov. 3, 479-487 (2004).
54. Yoshida, H. & Ihara, Y. Tau in paired helical filaments is functionally distinct from fetal tau: Assembly incompetence of paired helical filament-tau. J. Neurochem. 61, 1183-1186 (1993).
55. Johnson, G. V. & Bailey, C. D. Tau, where are we now? J. Alzheimers Dis. 4, 375-398 (2002).
56. Hong, M., Chen, D. C., Klein, P. S. & Lee, V. M. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J. Biol. Chem. 272, 25326-25332 (1997).
57. Munoz Montano, J. R., Moreno, F. J., Avila, J. & Diaz Nido, J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett. 411, 183-188 (1997).
58. Lovestone, S. et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol. 4, 1077-1086 (1994).
59. Bhat, R. et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 278, 45937-45945 (2003).
60. Sengupta, A., Wu, Q., Grundke-Iqbal, I., Iqbal, K. & Singh, T. J. Potentiation of GSK-3-catalyzed Alzheimerlike phosphorylation of human tau by cdk5. Mol. Cell. Biochem. 167, 99-105 (1997).
61. Morfini, G. et al. A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J. 23, 2235-2245 (2004).
62. Hernandez, F., Borrell, J., Guaza, C., Avila, J. & Lucas, J. J. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3β in the brain but do not form tau filaments. J. Neurochem. 83, 1529-1533 (2002).
63. Lucas, J. J. et al. Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J. 20, 27-39 (2001).
64. Zhang, F., Phiel, C. J., Spece, L., Gurvich, N. & Klein, P. S. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J. Biol. Chem. 278, 33067-33077 (2003).
65. Szatmari, E. et al. A positive feedback loop between glycogen synthase kinase 3β and protein phosphatase 1 after stimulation of NR2B NMDA receptors in forebrain neurons. J. Biol. Chem. 280, 37526-37535 (2005).
66. Engel, T., Hernandez, F., Avila, J. & Lucas, J. J. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J. Neurosci. 26 5083-5090 (2006).
67. Boulton, T. G. et al. ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 65, 663-675 (1991).
68. Roder, H. M. & Ingram, V. M. Two novel kinases phosphorylate tau and the KSP site of heavy neurofilament subunits in high stoichiometric ratios. J. Neurosci. 11, 3325-3343 (1991).
69. Veeranna, A. et al. Mitogen-activated protein kinases (Erk1, 2) phosphorylate Lys-Ser-Pro (KSP) repeats in neurofilament proteins NF-H and NF-M. J. Neurosci. 18, 4008-4021 (1998).
70. Drewes, G. et al. Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J. 11 2131-2138 (1992).
71. Ferrer, I. et al. Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol. 11, 144-158 (2001).
72. Sawamura, N. et al. Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice. J. Biol. Chem. 276, 10314-10319 (2001).
73. Takashima, A., Noguchi, K., Sato, K., Hoshino, T. & Imahori, K. Tau protein kinase I is essential for amyloid β-protein-induced neurotoxicity. Proc. Natl Acad. Sci. USA 90, 7789-7793 (1993).
74. Takashima, A. et al. Exposure of rat hippocampal neurons to amyloid β peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 β. Neurosci. Lett. 203, 33-36 (1996).
75. Takashima, A. et al. Activation of tau protein kinase I/glycogen synthase kinase-3β by amyloid β peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci. Res. 31, 317-323 (1998).
76. Ferreira, A., Lu, Q., Orecchio, L. & Kosik, K. S. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A β. Mol. Cell. Neurosci. 9, 220-234 (1997).
77. Lee, M. S. et al. APP processing is regulated by cytoplasmic phosphorylation. J. Cell Biol. 163, 83-95 (2003).
78. Otth, C. et al. AβPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J. Alzheimers Dis. 4, 417-430 (2002).
79. Alvarez, A., Toro, R., Caceres, A. & Maccioni, R. B. Inhibition of tau phosphorylating protein kinase cdk5 prevents β-amyloid-induced neuronal death. FEBS Lett. 459, 421-426 (1999).
80. Town, T. et al. p35/Cdk5 pathway mediates soluble amyloid-β peptide-induced tau phosphorylation in vitro. J. Neurosci. Res. 69, 362-372 (2002).
81. Ryder, J. et al. Divergent roles of GSK3 and CDK5 in APP processing. Biochem. Biophys. Res. Commun. 312, 922-929 (2003).
82. Alvarez, G. et al. Lithium protects cultured neurons against β-amyloid-induced neurodegeneration. FEBS Lett. 453, 260-264 (1999).
83. Hoshi, M. et al. Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β. Proc. Natl Acad. Sci. USA 100 6370-6375 (2003).
84. Fillit, H. M. & Refolo, L. M. Advancing drug discovery for Alzheimer's disease. Curr. Alzheimer Res. 2, 105-107 (2005).
85. Hung, K.S. et al. Calpain inhibitor inhibits p35-p25-Cdk5 activation, decreases tau hyperphosphorylation and improves neurological function after spinal cord hemisection in rats. J. Neuropathol. Exp. Neurol. 64, 15-26 (2005).
86. Gould, T. D. & Manji, H. K. Glycogen synthase kinase-3: A putative molecular target for lithium mimetic drugs. Neuropsychopharmacol. 30, 1223-1237 (2005).
87. Noble, W. et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl Acad. Sci. USA 102, 6990-6995 (2005).
88. Nakashima, H. et al. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol. 110, 547-556 (2005).
89. Pickhardt, M. et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J. Biol. Chem. 280, 3628-3635 (2005).
90. Khlistunova, I. et al. Inducible expression of Tau repeat domain in cell models of tauopathy: Aggregation is toxic to cells but can be reversed by inhibitor drugs. J. Biol. Chem. 281, 1205-1214 (2006).
91. Lewis, J. et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nature Genet. 25, 402-405 (2000).
92. Patel, S., Doble, B. & Woodgett, J. R. Glycogen synthase kinase-3 in insulin and Wnt signalling: A double-edged sword? Biochem. Soc. Trans. 32, 803-808 (2004).
93. Fischer, P. M. Cyclin-dependent kinase inhibitors: Discovery, development and target rationale for different therapeutic applications. Drugs Fut. 30, 911-929 (2005).
94. Weishaupt, J. H. et al. Inhibition of CDK5 is protective in necrotic and apoptotic paradigms of neuronal cell death and prevents mitochondrial dysfunction. Mol. Cell. Neurosci. 24, 489-502 (2003).
95. Gillardon, F., Schrattenholz, A. & Sommer, B. Investigating the neuroprotective mechanism of action of a CDK5 inhibitor by phosphoproteome analysis. J. Cell. Biochem. 95, 817-826 (2005).
96. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
97. McInnes, C. & Fischer, P. M. Strategies for the design of potent and selective kinase inhibitors. Curr. Pharm. Des. 11, 1845-1863 (2005).
98. Fischer, P. M. The design of drug candidate molecules as selective inhibitors of therapeutically relevant kinases. Curr. Med. Chem. 11, 1563-1583 (2004).
99. Hanks, S. K. & Hunter, T. Protein kinases 6. The eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification. FASEB J. 9, 576-596 (1995).
100. Jeffrey, P. D. et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376, 313-320 (1995).
101. Otyepka, M., Bartova, I., Kriz, Z. & Koca, J. Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics. J. Biol. Chem. 281, 7271-7281 (2006).
102. Mapelli, M. et al. Mechanism of CDK5/p25 binding by CDK inhibitors. J. Med. Chem. 48, 671-679 (2005).
103. Tarricone, C. et al. Structure and regulation of the CDK5-p25(nck5a) complex. Mol. Cell 8, 657-669 (2001).
104. Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Rev. Drug. Discov. 1, 493-502 (2002).
105. Liu, Y. & Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations. Nature Chem. Biol. 2, 358-364 (2006).
106. Heron, N. M. et al. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg. Med. Chem. Lett. 16, 1320-1323 (2006).
107. Johnson, K. et al. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: Identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs. J. Neurochem. 93, 538-548 (2005).
108. Hoessel, R. et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclindependent kinases. Nature Cell Biol. 1, 60-67 (1999).
109. Meijer, L. & Raymond, E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem. Res. 36, 417-425 (2003).
110. Mettey, Y. et al. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity and cellular effects. J. Med. Chem. 46, 222-236 (2003).
111. Kinoshita, T. et al. Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative. Bioorg. Med. Chem. Lett. 16, 55-58 (2006).
112. Xiao, Z., Hao, Y., Liu, B. & Qian, L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk. Lymph. 43, 1763-1768 (2002).
113. Fischer, P. M. CDK versus GSK-3 inhibition: A purple haze no longer? Chem. Biol. 10, 1144-1146 (2003).
114. Leclerc, S. et al. Indirubins inhibit glycogen synthase kinase-3β and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 276, 251-260 (2001).
115. Polychronopoulos, P. et al. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclindependent kinases. J. Med. Chem. 47, 935-946 (2004).
116. Meijer, L. et al. GSK-3-selective inhibitors derived from tyrian purple indirubins. Chem. Biol. 10, 1255-1266 (2003).
117. Marko, D. et al. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br. J. Cancer 84 283-289 (2001).
118. Davies, T. G. et al. Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure 9, 389-397 (2001).
119. Damiens, E., Baratte, B., Marie, D., Eisenbrand, G. & Meijer, L. Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: Induction of endoreplication following prophase arrest. Oncogene 20, 3786-3797 (2001).
120. Heredia, A. et al. Indirubin-3′-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication. AIDS 19, 2087-2095 (2005).
121. Huang, M., Wang, Y., Cogut, S. B., Mitchell, B. S. & Graves, L. M. Inhibition of nucleoside transport by protein kinase inhibitors. J. Pharmacol. Exp. Ther. 304, 753-760 (2003).
122. Adachi, J. et al. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J. Biol. Chem. 276, 31475-31478 (2001).
123. Knockaert, M. et al. Independent actions on cyclindependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins. Oncogene 23, 4400-4412 (2004).
124. Jautelat, R. et al. From the insoluble dye indirubin towards highly active, soluble CDK2-inhibitors. ChemBioChem 6, 531-540 (2005).
125. De Azevedo, W. F. et al. Inhibition of cyclin-dependent kinases by purine analogues: Crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243, 518-526 (1997).
126. De Azevedo, W. F. Jr, Canduri, F. & Da Silveira, N. J. F. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem. Biophys. Res. Commun. 293, 566-571 (2002).
127. Legraverend, M. et al. Cyclin-dependent kinase inhibition by new C-2 alynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. J. Med. Chem. 43, 1282-1292 (2000).
128. Dreyer, M. K. et al. Crystal structure of human cyclindependent kinase 2 in complex with the adenine-derived inhibitor H717. J. Med. Chem. 44, 524-530 (2001).
129. Arris, C. E. et al. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J. Med. Chem. 43, 2797-2804 (2000).
130. Vesely, J. et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 224, 771-786 (1994).
131. Wang, Z. et al. Structural basis of inhibitor selectivity in MAP kinases. Structure 6, 1117-1128 (1998).
132. Gray, N. S. et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533-538 (1998).
133. Chang, Y. T. et al. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 6, 361-375 (1999).
134. Schulze-Gahmen, U. et al. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomucine and isopentyladenine. Proteins 22, 378-391 (1995).
135. Shum, P. W. et al. The design and synthesis of purine inhibitors of CDK2. III. Nucleosides, Nucleotides Nucleic Acids 20, 1067-1078 (2001).
136. Ohori, M. et al. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem. Biophys. Res. Commun. 336, 357-363 (2005).
137. Martinez, A., Alonso, M., Castro, A., Perez, C. & Moreno, F. J. First non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 45, 1292-1299 (2002).
138. Martinez, A. et al. SAR and 3D-QSAR studies on thiadiazolidinone derivatives: Exploration of structural requirements for glycogen synthase kinase 3 inhibitors. J. Med. Chem. 48, 7103-7112 (2005).
139. Cohen, M. S., Zhang, C., Shokat, K. M. & Taunton, J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308, 1318-1321 (2005).
140. Conde, S., Perez, D. I., Martinez, A., Perez, C. & Moreno, F. J. Thienyl and phenyl α-halomethyl ketones: New inhibitors of glycogen synthase kinase (GSK-3β) from a library of compound searching. J. Med. Chem. 46, 4631-4633 (2003).
141. Ahn, J. S. et al. Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation. Chem. Biol. 12, 811-823 (2005).
142. Sharma, P. et al. Identification of substrate binding site of cyclin-dependent kinase 5. J. Biol. Chem. 274, 9600-9606 (1999).
143. Chin, K. T. et al. Identification and structure characterization of a Cdk inhibitory peptide derived from neuronal-specific Cdk5 activator. J. Biol. Chem. 274, 7120-7127 (1999).
144. Kesavapany, S. et al. Neuronal cyclin-dependent kinase 5: Role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide. Biochim. Biophys. Acta 1697, 143-153 (2004).
145. Amin, N. D., Albers, W. & Pant, H. C. Cyclin-dependent kinase 5 (cdk5) activation requires interaction with three domains of p35. J. Neurosci. Res. 67, 354-362 (2002).
146. Zheng, Y. L., Li, B. S., Amin, N. D., Albers, W. & Pant, H. C. A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells. Eur. J. Biochem. 269, 4427-4434 (2002).
147. Zheng, Y.-L. et al. A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. EMBO J. 24, 209-220 (2005).
148. Molina, D. M., Grewal, S. & Bardwell, L. Characterization of an ERK-binding domain in microphthalmia-associated transcription factor and differential inhibition of ERK2-mediated substrate phosphorylation. J. Biol. Chem. 280, 42051-42060 (2005).
149. Lipinski, C. A. Filtering in drug discovery. Ann. Rep. Comput. Chem. 1, 155-168 (2005).
150. Bertrand, J. A. et al. Structural characterization of the GSK-3β active site using selective and non-selective ATP-mimetic inhibitors. J. Mol. Biol. 333, 393-407 (2003).
151. Brown, N. R. et al. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J. Biol. Chem. 274, 8746-8756 (1999).
152. ter Haar, E. et al. Structure of GSK3β reveals a primed phosphorylation mechanism. Nature Struct. Biol. 8, 593-596 (2001).
153. Davies, T. G. et al. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nature Struct. Biol. 9, 745-749 (2002).
154. Clare, P. M. et al. The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism. J. Biol. Chem. 276, 48292-48299 (2001).
155. Bramson, H. N. et al. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): Design, synthesis, enzymatic activities and X-ray crystallographic analysis. J. Med. Chem. 44, 4339-4358 (2001).
156. Richardson, C. M. et al. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: Protein structure-guided design and SAR. Bioorg. Med. Chem. Lett. 16, 1353-1357 (2006).
157. Brown, N. R., Noble, M. E., Endicott, J. A. & Johnson, L. N. The structural basis for specificity of substrate and recruitment peptides for cyclindependent kinases. Nature Cell Biol. 1, 438-443 (1999).
158. Helal, C. J. et al. Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease. Bioorg. Med. Chem. Lett. 14, 5521-5525 (2004).
159. Leost, M. et al. Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 267, 5983-5994 (2000).
160. Sondhi, S. M. et al. Synthesis of acridinyl-thiazolino derivatives and their evaluation for anti-inflammatory, analgesic and kinase inhibition activities. Bioorg. Med. Chem. 13, 4291-4299 (2005).
161. Voigt, B. et al. Novel CDK inhibition profiles of structurally varied 1-aza-9-oxafluorenes. Bioorg. Med. Chem. Lett. 15, 823-825 (2005).
162. Engler, T. A. et al. Novel, potent and selective cyclin D1/CDK4 inhibitors: Indolo[6,7-a]pyrrolo[3,4-c]carbazoles. Bioorg. Med. Chem. Lett. 13, 2261-2267 (2003).
163. Clark, D. E. Computational prediction of blood-brain barrier permeation. Annu. Rep. Med. Chem. 40, 403-415 (2005).
164. Norinder, U. & Haeberlein, M. Computational approaches to the prediction of the blood-brain distribution. Adv. Drug Delivery Rev. 54, 291-313 (2002).